Poundland moves to new ownership under Gordon Brothers
Pepco Group has finalised the sale of its Poundland business to Gordon Brothers International LLC, marking a significant step in the company's strategy to focus on its higher margin Pepco retail operations.
The transaction, completed in June 2025, is expected to simplify Pepco Group's structure and enhance overall profitability.
The sale of Poundland, a UK-based discount retailer operating over 800 stores and employing around 16,000 people, aligns with Pepco Group's decision to concentrate on its core Pepco brand, which primarily offers clothing and general merchandise.
In the previous financial year, Poundland accounted for about one-third of group revenues but contributed only 5% to earnings before interest, tax, depreciation, and amortisation (EBITDA).
The divestment is designed to improve revenue growth, increase margins, and boost cash generation by focusing on the more profitable Pepco operations across Europe.
Gordon Brothers is a global advisory, restructuring, and investment firm that specialises in helping businesses with asset management, turnaround, and growth strategies.
Established over a century ago, the company works across various industries to manage and revitalise brands and operations.
Their acquisition of Poundland fits within their wider approach to investing in retail businesses and supporting their development.
Poundland was sold for nominal consideration, with Pepco retaining secured and unsecured loans amounting to £30 million as part of the deal.
A restructuring plan involving the transfer of certain financial arrangements is pending approval by the High Court in England. Under the new ownership, Poundland will continue to operate under its established brand in the UK, led by current managing director Barry Williams.
Pepco Group expects to retain a minority investment interest, allowing it to maintain some involvement in Poundland's future performance.
Both companies have also agreed on transitional service arrangements to support operations during the changeover.
This move is part of a broader strategy by Pepco Group to streamline its portfolio and focus on sectors delivering higher returns and stronger growth prospects, moving away from fast-moving consumer goods (FMCG) and potentially considering further divestments in related businesses.
Several news outlets, including the BBC, have reported that Poundland was sold for approximately £1. However, Pepco's official statement did not disclose a specific sale price, instead referring only to the shares being sold for "nominal consideration," which typically means a very small or symbolic amount.
"Poundland moves to new ownership under Gordon Brothers" was originally created and published by Retail Insight Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Cheshire farmhouse with indoor swimming pool and eight acres for sale at £2.5m
An indoor swimming pool, barns, and eight acres of land are among the features of a four-bedroom farmhouse now up for sale. The property in Mobberley, listed at £2,500,000, includes the main farmhouse, several outbuildings, and landscaped gardens, according to the listing. Approached via Smith Lane, a York stone-paved courtyard provides access to the main house, a detached double garage, a converted barn, and covered storage or parking area. (Image: Wright Marshall Estate Agents, Knutsford) The courtyard is described as offering parking for a 'large number of different style of vehicles'. Inside the main house, a small porch leads to an oak-floored reception hallway. Two reception rooms branch off from this space, one described as a 'traditional snug' and the other as the main family lounge, which features a fireplace with a log burner and French doors opening onto a patio. (Image: Wright Marshall Estate Agents, Knutsford) The kitchen is open plan, with a central island, skylights, and large windows. Bi-folding doors overlook the gardens. The listing states the kitchen is 'flooded with an abundance of natural light' and described as the 'true heart of this desirable family home'. Off the kitchen, there is a cloakroom, a utility room, and a second door to the courtyard. Upstairs, there are four double bedrooms. (Image: Wright Marshall Estate Agents, Knutsford) The main bedroom has a five-piece en-suite, including 'his & hers basins' and a freestanding roll top claw foot bath, plus a television. The remaining bedrooms are served by a four-piece bathroom with separate shower and bath. Outbuildings include a converted barn known as 'The Big Barn', which has been used as offices and a workshop. The barn has water, waste, and electrical supply, along with a two-piece cloakroom. The ground floor is divided into several areas, while the first floor features a mezzanine, a playroom, and another room. Both internal and external fire escapes are present. Another open-fronted barn is used for storing machinery and equipment. (Image: Wright Marshall Estate Agents, Knutsford) The pool house, built about 30 years ago, is described as being in a European style and contains changing rooms, a sauna, kitchen, and plant room. The pool is around four feet deep. Landscaped gardens include trees, shrubs, mature hedgerows, and seating areas. The listing mentions 'far reaching views over the Cheshire countryside'. Eight acres of land surround the property, currently left to grow and cut annually. The property is offered with no onward chain.
Yahoo
17 minutes ago
- Yahoo
The Funnels Guys Announces GoHighLevel Expert Sales Funnel Services for Experts, Entrepreneurs, Coaches & Consultants
LONDON, UK / / June 15, 2025 / The Funnels Guys is an award-winning digital marketing agency specializing in ClickFunnels and GHL solutions. The company is launching premium funnel services made especially for experts, entrepreneurs, coaches, and consultants. The Funnels Guys strive to empower businesses of all sizes, committing themselves to maximizing that potential through the creation of expert sales funnels that ensure online success. Some say those who feel that luck's on their side are usually the ones who work the hardest. Cormac Reynolds leads The Funnels Guys with 15 committed marketing professionals who have enormous experience in digital marketing and sales funnel optimization. "The new premium services will provide the customized solutions that professionals seek to improve their online presence and conversion journey." Our premium sales funnel services focus on unique demands put forth by an expert or an entrepreneur so that they can always successfully find their audience and turn leads into loyal clients," said Cormac Reynolds, Founder and CEO of The Funnels Guys. "We will be giving them everything they need in terms of tools and strategies for coaches and consultants in an extremely competitive environment Today." The Service Offerings Include Opt-in Pages (Squeeze Pages): Generate successful leads with persuasive content. Long-Form Sales Pages: Construct all pages to ensure maximum conversion and/or engagement. Video Sales Letters (VSLs): Utilize promotional videos for sales enhancement. Thank You Pages: Develop a better customer experience after conversion. Upsell and Downsell Pages (OTO): Optimize customer efficiency for revenue maximization. Order Forms and Confirmation Pages: Provide a smooth, unproblematic purchase process. Webinar and Membership Pages Formulate societies and maximize ongoing value. With a historic track record of consistent performance, The Funnels Guys make use of innovation along with hands-on efforts to maximize returns to clients. The work of making all such notable publications so renowned as their credible evidence of being leaders in the industry event with The Funnels Guys. Trust and transparency are number one at The Funnels Guys business principles. It is all about building long-term relationships with clients, remaining ethical in all dealings, and pledging results that will make an impact. About The Funnels Guys The Funnels Guys are a superior digital marketing agency entirely focused on creating the highest converting sales funnel campaigns tailored to different business demands. Meeting customers' business needs has really been in business all because of The Funnels Guys amazing team which handles all sorts of professional services intended to maximize clients' online sales strategies and render fantastic results across various industries. Do check our Instagram, Facebook, Trustpilot & Twitter Media Contact: The Funnels GuysE-mail: hello@ & Country: London, UKContact Person Name: Cormac ReynoldsWebsite: SOURCE: The Funnels Guys View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor
– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe mechanistic insights for greater potency with verekitug compared to tezepelumab – – Supports potentially differentiated profile of verekitug across a broad range of inflammatory diseases, including severe asthma, chronic obstructive pulmonary disease (COPD) and chronic rhinosinusitis with nasal polyps (CRSwNP) – WALTHAM, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the presentation of translational pharmacology modeling data supporting verekitug's Thymic Stromal Lymphopoietin (TSLP) receptor targeting as a mechanism for greater potency when compared to treatments targeting the TSLP ligand. Data were presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress taking place June 13-16, 2025, in Glasgow, United Kingdom. TSLP is a cytokine that is a key driver of the inflammatory response in major allergic and inflammatory diseases, such as asthma, where disruption of TSLP signaling has been clinically validated as an effective treatment approach. Because TSLP is a target upstream in the inflammatory cascade, blocking the TSLP receptor presents an opportunity for a single treatment to impact the drivers of multiple pathological inflammatory processes across a broad set of diseases. Upstream is developing verekitug in multiple severe respiratory diseases including severe asthma, COPD, and CRSwNP. Verekitug is the only monoclonal antibody currently in clinical development that targets and inhibits the TSLP receptor. 'These data reinforce our belief in the differentiated profile of verekitug, as the model elucidates important biologic parameters that drive the differentiated rapid, substantial and sustained treatment effects observed through TSLP receptor inhibition with verekitug,' said Aaron Deykin, MD, Chief Medical Officer and Head of Research & Development of Upstream Bio. 'We look forward to further assessing the potential translation of this unique mechanism into clinical benefit in patients with severe respiratory diseases, first with top-line Phase 2 clinical data in CRSwNP in the third quarter of this year followed by data in severe asthma in the first half of 2026.' Data presented used an in silico system pharmacology modeling approach to provide a mechanism-based understanding for the observed potency of verekitug and are summarized as follows: Semi-mechanistic pharmacokinetic/pharmacodynamic (PK/PD) models were built using the same biological and drug-specific parameters for verekitug and tezepelumab and populated with observed clinical data for verekitug and published clinical data for tezepelumab. Across a range of doses, PK/PD model simulations predict complete and sustained inhibition of the TSLP/TSLPR complex with verekitug compared to tezepelumab. Dose-response model simulations predict that potent inhibition of the TSLP/TSLPR complex would result in a greater reduction in fractional exhaled nitric oxide (FeNO), a biomarker of lung inflammation. Modeling data indicated that the greater predicted reduction of FeNO observed with verekitug, compared with published data for tezepelumab, is potentially driven by lower expression levels of the TSLP receptor over time versus the ligand, as well as slower protein turnover time for the TSLP receptor versus the ligand. These data indicate the differentiated mechanism of TSLP receptor targeting with verekitug may drive the greater potency observed with this approach as compared with targeting the TSLP ligand. Phase 2 clinical trials are ongoing in severe asthma and in CRSwNP and planned in COPD to assess the potential translation of verekitug's unique targeting mechanism into clinical benefit for patients. A digital version of the presentation can be found on the Upstream Bio website. About TSLP and TSLPR BlockadeThymic Stromal Lymphopoietin (TSLP) is a cytokine that is a key driver of the inflammatory response in major allergic and inflammatory diseases, such as asthma, where disruption of TSLP signaling has been clinically validated as an effective therapeutic strategy. TSLP activation is one of the first events in the inflammatory cascade stimulated by allergens, viruses and other triggers, initiating the activation of downstream targets such as IL-4, IL-5, IL-13, IL-17 and IgE. Because TSLP is a target upstream in the inflammatory cascade, blocking the TSLP receptor (TSLPR) presents an opportunity for a single treatment to impact the drivers of multiple pathological inflammatory processes across a broad set of diseases. About VerekitugVerekitug is a novel recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to the TSLP receptor and inhibits proinflammatory signaling initiated by TSLP. It is the only monoclonal antibody currently in clinical development that targets and inhibits the TSLP receptor. Verekitug is currently being evaluated in two separate multi-national, placebo-controlled, randomized Phase 2 clinical trials, the VALIANT trial in patients with severe asthma (NCT06196879) and the VIBRANT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) (NCT06164704). Upstream Bio is also initiating a Phase 2 clinical trial (NCT06981078) of verekitug in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). In preclinical studies, verekitug demonstrated high occupancy of the TSLP receptor and potent inhibition of TSLP signaling. Additionally, verekitug inhibited cytokine production from both CD4+ T cells and ILC2 cells and completely suppressed skin allergic reactions in a non-human primate model, suggesting that it may be effective against multiple types of inflammation. Three clinical trials have been completed for verekitug, including a Phase 1 single-ascending dose (SAD) clinical trial and a Phase 1b multiple-ascending dose (MAD) clinical trial. In these trials, verekitug was well tolerated, had no clinically meaningful immunogenicity, and showed a predictable and consistent pharmacokinetic profile and high subcutaneous bioavailability. About Upstream BioUpstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and is initiating development in chronic obstructive pulmonary disease. Upstream Bio's team is committed to maximizing verekitug's unique attributes to address the substantial unmet needs for patients underserved by today's standard of care. To learn more, please visit Forward-Looking StatementsThis press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'continue,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'predict,' 'project,' 'seeks,' 'should,' 'target,' 'will' and variations of these words or similar expressions. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, express or implied statements regarding: the clinical development of verekitug for the treatment of severe asthma, CRSwNP and COPD, including the initiation, timing, progress and results of ongoing and planned clinical trials; expectations for future discussions with regulatory authorities and the potential of the endpoints of the Company's clinical trials to produce data that could support submissions for product approval; expectations regarding the differentiation, safety, efficacy or tolerability of verekitug; expectations regarding the translation of pharmacology modeling data of verekitug to clinical effects; and assessments comparing non-head-to-head clinical data of verekitug to published data for tezepelumab. Any forward-looking statements in this press release are based on the Company's current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Readers are cautioned that actual results, levels of activity, safety, efficacy, performance or events and circumstances could differ materially from those expressed or implied in the Company's forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to: Upstream Bio's ability to advance verekitug through clinical development, and to obtain regulatory approval of and ultimately commercialize verekitug on the expected timeline, if at all; the initiation, timing, progress and results of clinical trials; Upstream Bio's ability to fund its development activities and achieve development goals; Upstream Bio's dependence on third parties to conduct clinical trials and manufacture verekitug, and commercialize verekitug, if approved; Upstream Bio's ability to attract, hire and retain key personnel, and protect its intellectual property; Upstream Bio's financial condition and need for substantial additional funds in order to complete development activities and commercialize verekitug, if approved; regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; Upstream Bio's competitors and industry; and other risks and uncertainties described in greater detail under the caption 'Risk Factors' in Upstream Bio's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the SEC. Any forward-looking statements represent Upstream Bio's views only as of today and should not be relied upon as representing its views as of any subsequent date. Upstream Bio explicitly disclaims any obligation or undertaking to update any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based except to the extent required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. CONTACT: Investor and Media Contact: Meggan Buckwell Director, Corporate Communications and Investor Relations ir@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
